Related Experiment Videos
[TRALI: from diagnosis to prevention].
1Centre hospitalier universitaire de Nantes, laboratoire d'immunologie leucoplaquettaire, Quai Moncousu, Nantes, France. jymuller@chu-nantes.fr
Summary
Transfusion-Related Acute Lung Injury (TRALI) is a serious respiratory complication after blood transfusions. Its exact cause remains unclear, but it involves lung inflammation and fluid buildup, often requiring a predisposing condition.
Area of Science:
- Transfusion Medicine
- Immunology
- Pulmonology
Background:
- Transfusion-Related Acute Lung Injury (TRALI) is a leading cause of transfusion-associated mortality.
- TRALI is characterized by acute respiratory distress syndrome (ARDS) developing within six hours of blood product transfusion.
- The incidence of TRALI ranges from 1 in 5,000 to 1 in 500,000 transfusions.
Purpose of the Study:
- To review the current understanding of TRALI's pathophysiology.
- To discuss the various proposed etiological factors, including antibodies and lipids.
- To highlight the need for improved donor screening and management strategies.
Main Methods:
- Review of existing literature on TRALI.
- Analysis of proposed mechanisms involving immune and non-immune factors.
- Discussion of clinical presentation and risk factors.
Main Results:
- TRALI involves non-cardiogenic pulmonary edema due to neutrophil activation and endothelial damage.
- Etiologies include antibodies (anti-HLA class I, II, granulocyte antigens) and granulocyte-activating lipids.
- A predisposing condition is often necessary, alongside triggering factors, leading to leucostasis.
- Multiparous women are frequently implicated as donors.
Conclusions:
- The precise etiology of TRALI is complex and multifactorial.
- Current guidelines for antibody screening and donor deferral are insufficient.
- Further research is needed to establish definitive diagnostic and preventative measures for TRALI.